Cost-Effectiveness of Nintedanib for Patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD)

por Westerink, Lotte, Nicolai, Jelmer Lennart Jens, Postma, Maarten Jacobus, van Boven, Job Frank Martien, Boersma, Cornelis
Publicado 2022

Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations

por Westerink, Lotte, Nicolai, Jelmer L. J., Samuelsen, Carl, Smit, Hans J. M., Postmus, Pieter E., Griebsch, Ingolf, Postma, Maarten J.
Publicado 2020